Special report: Highlights of the 75th European Atherosclerosis Society congress

Atherosclerosis

Volumn 181, Issue 2, 2005, Pages

  Shepherd, James ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; NICOTINIC ACID; OLMESARTAN; ROSUVASTATIN; SIMVASTATIN; UBIQUINONE; VALSARTAN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; HUMAN; LIFESTYLE; MEDICAL RESEARCH; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SAFETY;

ATHEROSCLEROSIS; EUROPE; HUMANS; RISK FACTORS;

EID: 22544459092     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.05.021     Document Type: Conference Paper

References (63)

1. Shepherd J. Treating to new targets: anatomy of a clinical trial. Atherosclerosis 2005;6(Suppl):99.
2. La Rosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
3. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
4. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs 2004;64(Suppl 2):43-60.
5. Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol 1998;82:3Q-12Q.
6. Rosenson RS. Statins: can the new generation make an impression? Expert Opin Emerg Drugs 2004;9:269-79.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
8. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-10.
9. Avezum A, Makdisse M, Spencer F, et al. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2005;149:67-73.
10. McLaughlin TJ, Soumerai SB, Willison DJ, et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. Arch Intern Med 1996;156:799-805.
11. Gurwitz JH, Gore JM, Goldberg RJ, et al. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. National Registry of Myocardial Infarction. Ann Intern Med 1996;124:283-91.
12. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med 1996;124:292-8.
13. Datino T, Martinez-Selles M, Bueno H. Statin use after acute myocardial infarction in patients 89 years and older. In: Poster presented at the 75th European Atherosclerosis Society congress. 2005.
14. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
15. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
16. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
17. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
18. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
19. Shipley MJ, Pocock SJ, Marmot HG. Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18-year follow-up of the Whitehall Study. BMJ 1991;303:89-92.
20. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, et al. Total cholesterol and risk of mortality in the oldest old. Lancet 1997;350:1119-23.
21. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke: 13000 strokes in 450000 people in 45 prospective cohorts. Lancet 1995;346:1647-53.
22. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
23. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol 2002;39:1567-73.
24. Marz W, Siekmeier R, Muller HM, et al. Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy. J Cardiovasc Pharmacol Ther 2000;5:275-9.
25. Rauchhaus M, Coats AJS, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000;356:930-3.
26. Krum H, Carretta E, Latini R, et al. Are statins of clinical benefit in patients with established systolic chronic heart failure? A retrospective analysis of 5010 patients enrolled in Val-HeFT. Circulation 2004;110(Suppl III):111-680.
27. Ray JG, Gong Y, Sykora K, Tu JV. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 2005;165:62-7.
28. Martinez E, Dominguez M, Martinez-Selles M. Rate of statin use in patients with advanced systolic heart failure. Prognostic implications. In: Poster presented at the 75th European Atherosclerosis Society congress. 2005.
29. Tavazzi L, Tognoni G, Franzosi MG, et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Failure 2004;6:635-41.
30. Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991;67:1185-9.
31. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diab Care 2004;27:2444-9.
32. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diab Care 2004;27:1047-53.
33. Tudor C, Jeberean R, Clepce R. Factors that influence HDLcholesterol actions and levels and the cardiovascular protection that it provides to patients with diabetes. In: Poster presented at the 75th European Atherosclerosis Society congress. 2005.
34. Martinez B, Molinero E, Caso R, et al. Inflammatory and thrombogenic factors involved in the genesis of coronary atherosclerosis. In: Poster presented at the 75th European Atherosclerosis Society congress. 2005.
35. Martinez B, Molinero E, Caso R, et al. Ischaemic cardiopathy and renal function. Is it a new independent risk factor? In: Poster presented at the 75th European Atherosclerosis Society congress. 2005.
36. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? Am J Kid Dis 1998;32:853-906.
37. Brunner FP, Selwood NH. Profile of patients on RRT in Europe and death rates due to major causes of death groups. The EDTA Registration Committee. Kidney Int 1992;38(Suppl):4-15.
38. Fried LF, Shlipak MG, Crump C, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003;41:1364-72.
39. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003;41:47-55.
40. Cicero AFG, Derosa G, Bernardi R, Linarello S, Gaddi AV. Reaching target in metabolic syndrome patients: olmesartan 20 mg + rosuvastatin 10 mg versus losartan 50 mg + atorvastatin 10 mg. In: Poster presented at the 75th European Atherosclerosis Society congress. 2005.
41. Lalic NM, Ostojic M, Lalic K, et al. Multiple versus single vessel coronary heart disease: influence of higher insulin resistance and hypofibrinolysis in type 2 diabetic patients. In: Poster presented at the 75th European Atherosclerosis Society congress. 2005.
42. Kanjuh V, Lalic NM, Ostojic M, et al. Recurrency of myocardial infarction in type 2 diabetes: the role of metabolic and fibrinolytic factors. In: Poster presented at the 75th European Atherosclerosis Society congress. 2005.
43. Festa A, D'Agostino Jr R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002;51:1131-7.
44. Kohler HP, Grant PJ. Plasminogen activator inhibitor type 1 and coronary heart disease. N Engl J Med 2000;342:1792-801.
45. Juhan-Vague I, Alessi MC, Vague P. Increased plasminogen activator inhibitor-1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991;34:457-62.
46. De Taeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 2005;5:149-54.
47. Reid AW, Reid DB, Roditi GH. Vascular imaging: an unparalleled decade. J Endovasc Ther 2004;11(Suppl 2):II163-79.
48. Flachskampf FA, Decoodt P, Fraser AG, Daniel WG, Roelandt JR. Guidelines from the Working Group. Recommendations for performing transesophageal echocardiography. Eur J Echocardiogr 2001;2:8-21.
49. Chrissos AA, Tapanlis EN, Peristeris D, et al. Location and clinical importance of atherosclerotic aortic plaques detected by transesophageal echocardiography. In: Poster presented at the 75th European Atherosclerosis Society congress. 2005.
50. Amarenco P, Cohen A, Tzourio C, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1994;331:1474-9.
51. The French Study of Aortic Plaques in Stroke Group. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med 1996;334:1216-21.
52. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging Circulation 1986;74:1399-406.
53. Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intima-media thickness progression in asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996;101:627-34.
54. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999;340:14-22.
55. Bots ML, Grobbee DE. Intima media thickness as a surrogate marker for generalised atherosclerosis. Cardiovasc Drugs Ther 2002;16:341-51.
56. Crouse 3rd JR, Grobbee DE, O'Leary DH, et al. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis - the rationale and methodology of the METEOR study. Cardiovasc Drugs Ther 2004;18:231-8.
57. Crouse 3rd JR, O'Leary D, Palmer M, Riachlen J, METEOR investigators. Measuring effects on intima media thickness: an evaluation of rosuvastatin (METEOR) - baseline characteristics of randomized patients. In: Poster presented at the 75th European Atherosclerosis Society congress. 2005.
58. Virmani R, Burke AP, Kolodgie FD, Farb A. Pathology of thincap fibroatheroma: a type of vulnerable plaque. J Interv Cardiol 2003;16:267-72.
59. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc Pathol 2004;13:125-38.
60. Hatsukami TS, Ross R, Polissar NL, Yuan C. Visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging. Circulation 2000;102:959-64.
61. Cai JM, Hatsukami TS, Ferguson MS, et al. Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. Circulation 2002;106:1368-73.
62. Saam T, Ferguson MS, Yarnykh VL, et al. Quantitative evaluation of carotid plaque composition by in vivo MRI. Arterioscler Thromb Vasc Biol 2005;25:234-9.
63. Saam T, Yuan C, Zhao X-Q, et al. Rosuvastatin treatment and its effects on plaque composition of carotid atherosclerosis in moderately hypercholesterolemic subjects: a high-resolution magnetic resonance imaging trial. In: Poster presented at the 75th European Atherosclerosis Society congress. 2005.